Results 41 to 50 of about 302,208 (172)

Harnessing the power of oncolytic viruses for advancing cancer therapy

open access: yesCancer Treatment and Research Communications
Oncolytic viruses are a novel and promising approach to cancer treatment. These viruses are either naturally occurring or genetically engineered to target and kill cancer cells while sparing healthy tissue.
Yismaw Alemie Alemayehu   +1 more
doaj   +1 more source

Multifunctional Nanovaccine‐Radiotherapy Synergy Drives Anti‐Tumor Immunity via Multi‐Cascade Cell Death for Pancreatic Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Machine‐learning‐driven transcriptomic analysis identifies FSTL3 as a key tumor‐microenvironment regulator in desmoplastic pancreatic adenocarcinoma. A cRGD‐modified liposome co‐loading gemcitabine and siFSTL3 serves as an irradiation‐triggered in situ nanovaccine. It synergizes with radiotherapy to induce ferroptosis and immunogenic cell death through
Chengyi Huang   +11 more
wiley   +1 more source

Collagen‐Binding IL‐15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self‐Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity

open access: yesAdvanced Science, EarlyView.
Repurposing the dense tumor stroma from a physical barrier into an anchoring scaffold, an engineered oncolytic adenovirus encoding IL15C‐CBD overcomes the immunosuppressive microenvironment in triple‐negative breast cancer. Intratumoral viral replication secretes this collagen‐anchored immunocytokine, forming a localized cytokine depot.
Yaqi Yang   +14 more
wiley   +1 more source

Oncolytic virotherapy using neural stem cells as a novel treatment option for glioblastoma multiforme

open access: yesMedComm – Oncology, 2023
The most deadly and aggressive form of brain cancer is called a glioblastoma multiforme. Following diagnosis, the median duration of survival is only 14 months.
Tanvir Ahmed
doaj   +1 more source

Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics

open access: yesFrontiers in Molecular Biosciences, 2022
Oncolytic viruses have made a significant inroad in cancer drug development. Numerous clinical trials are currently investigating oncolytic viruses both as single agents or in combination with various immunomodulators.
Virginia Corbett   +3 more
doaj   +1 more source

Engineered Peptide Self‐Assembled Nanofibers for Enhanced STING Activation: A Promising Nanodelivery Platform for Immunotherapy of Pediatric Solid Tumors

open access: yesAdvanced Science, EarlyView.
An engineered peptide self‐assembled nanofiber platform, designed to replicate STING–cGAMP binding motifs, facilitates pH‐responsive cytosolic delivery of cGAMP, enhances the endoplasmic reticulum with high efficiency, and robustly activates the STING pathway.
Yubin He   +6 more
wiley   +1 more source

Development of oncolytic viruses for cancer therapy

open access: yes, 2021
Oncolytic virotherapy is a therapeutic approach that uses replication-competent viruses to kill cancers. The ability of oncolytic viruses to selectively replicate in cancer cells leads to direct cell lysis and induction of anticancer immune response ...
Poh, Chit Laa *   +3 more
core   +1 more source

CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells

open access: yesAdvanced Science, EarlyView.
AARS2 functions as an intracellular lactate sensor and lactyltransferase, catalyzing CD112 K412 lactylation to block ubiquitination‐dependent degradation and stabilize CD112. This pathway suppresses CD8+ T‐cell and NK‐cell cytotoxicity, enabling dual immune evasion.
Zhuoshuo Xu   +6 more
wiley   +1 more source

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances [PDF]

open access: yes, 2016
Oncolytic viruses are multifunctional anticancer agents with huge clinical potential, and have recently passed the randomized Phase III clinical trial hurdle.
Relph, KL   +4 more
core   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy